

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-17. (Canceled)

18. (Previously presented) A polynucleotide encoding a fusion protein, the fusion protein comprising at least one pan DR binding peptide selected from the formula R_1 - R_2 - R_3 - R_4 - R_5 , wherein:

R_1 is an amino acid followed by alanine or lysine;

R_2 is selected from the group consisting of tyrosine, or phenylalanine;

R_3 is 3 or 4 amino acids, wherein each amino acid is independently selected from the group consisting of alanine, isoleucine, serine, glutamic acid and valine;

R_4 is selected from the group consisting of threonine-leucine-lysine, lysine-threonine, or tryptophan-threonine-leucine-lysine (SEQ ID NO:16); and,

R_5 consists of 2 to 4 amino acids followed by an amino acid wherein each of the 2 to 4 amino acids is independently selected from the group consisting of alanine, serine, and valine (SEQ ID NOS:17-22, representing the pan DR binding peptide where R_4 in the pan DR binding peptide consists of tryptophan-threonine-leucine-lysine (SEQ ID NO:16)).

19. (Previously presented) An expression vector comprising the polynucleotide of claim 18.

20. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises multiple pan DR peptides.

21. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises a homopolymer of pan DR peptides.

22. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein comprises a heteropolymer of pan DR peptides.
23. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises a heteropolymer with repeating units.
24. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises a T helper peptide.
25. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises an antibody-inducing peptide.
26. (Previously presented) The polynucleotide of claim 18, wherein the fusion protein further comprises a CTL-inducing peptide.
- 27-65. (Canceled)